Aegerion Pharmaceuticals, Inc. 4
4 · Aegerion Pharmaceuticals, Inc. · Filed Feb 12, 2014
Insider Transaction Report
Form 4
Fitzpatrick Mark J.
Chief Financial Officer
Transactions
- Sale
Common Stock
2014-02-10$62.94/sh−2,814$177,113→ 7,236 total - Exercise/Conversion
Common Stock
2014-02-10$17.64/sh+7,500$132,300→ 13,350 total - Sale
Common Stock
2014-02-10$63.72/sh−900$57,348→ 6,336 total - Sale
Common Stock
2014-02-10$61.71/sh−3,300$203,643→ 10,050 total - Sale
Common Stock
2014-02-10$64.69/sh−486$31,439→ 5,850 total - Exercise/Conversion
Stock Option (right to buy)
2014-02-10−7,500→ 192,150 totalExercise: $17.64Exp: 2021-06-01→ Common Stock (7,500 underlying)
Footnotes (6)
- [F1]The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Plan"). The Plan was adopted for purposes of investment portfolio diversification.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.295 to $62.26, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.37 to $63.35, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.38 to $64.17, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.61 to $64.90, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F6]132,000 of the shares of common stock underlying this stock option vest over four years in equal monthly installments starting on June 1, 2011. 88,000 of the shares of common stock underlying this stock option vest over four years in equal monthly installments starting on the date of marketing approval for JUXTAPID TM (lomitapide) by the U.S. Food and Drug Administration.